Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study

Programmed cell death protein 1 (PD-1) inhibitors have demonstrated promising activity among patients with advanced soft tissue sarcomas (STS) in phase II trials. The purpose of this study was to assess the efficacy and safety of toripalimab (a novel PD-1 inhibitor) combined with doxorubicin as firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhiyong, Liu, Cuiping, Yao, Weitao, Gao, Songtao, Wang, Jiaqiang, Zhang, Peng, Ge, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Preclinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448405/
https://www.ncbi.nlm.nih.gov/pubmed/34001702
http://dx.doi.org/10.1097/CAD.0000000000001088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448405/
https://www.ncbi.nlm.nih.gov/pubmed/34001702
http://dx.doi.org/10.1097/CAD.0000000000001088

Ejemplares similares